Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Quality of Life × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 211 Carcinoma, Intraductal, Noninfiltrating 18 Breast Carcinoma In Situ 15 Neoplasm Metastasis 11 Breast Neoplasms, Male 11 Neoplasms 10 Ovarian Neoplasms 8 Inflammatory Breast Neoplasms 6 Glioblastoma 5 Endometrial Neoplasms 4 Central Nervous System Neoplasms 4 Prostatic Neoplasms 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Cancer Female 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Glioma 2 Fibroadenoma 2 ER+ Breast Cancer 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Wake Disorders 1 Sexuality 1 Sarcoma 1 Risk Reduction Behavior 1 Recurrence 1

Interventions

endostar protein 1 coenzyme Q10 1 apatinib 1 Yoga 1 Ubiquinone 1 Tamoxifen 1 Referral and Consultation 1 Palliative Care 1 Oxaliplatin 1 Melatonin 1 Exercise 1 Educational Status 1 Chemoradiotherapy 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00784680 2009-05-01

ATAC - Quality of Life Sub-Protocol

AstraZeneca

Phase 3 Completed

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon ⚡